/
/
COVID Vaccine Responses Are Limited in Blood Cancer Patients
COVID Vaccine Responses Are Limited in Blood Cancer Patients image
COVID Vaccine Responses Are Limited in Blood Cancer Patients
Posted May 26, 2021

According to investigators at the University of Pennsylvania School of Medicine, a large percentage of blood cancer patients do not develop adequate antibodies to the COVID-19 vaccines. The study results were based on a small number (28) of blood cancer patients. 

It has been unclear how blood cancer patients will respond to the COVID vaccines. Will sufficient antibodies be developed? Blood cancer patients were not allowed to be included in the initial COVID-19 clinical trials. This lingering research question is an important one for AML patients as communities across the world open back up.

Blood cancer patients are at higher risk of COVID complications, with mortality rates exceeding 30%. Blood cancer patients can also develop prolonged shedding of infectious COVID-19, often lasting several months. It makes sense that blood cancer patients should be first in line for the vaccines. 

The investigators studied COVID-19 antibody responses in 28 blood cancer patients [chronic lymphocytic leukemia (CLL) (29.4%), lymphoma (31.3%), multiple myeloma (43%) and myeloid malignancies (5.97%)] seen at UPMC Hillman Cancer Center who had received two doses of either the Moderna or Pfizer vaccine. The median time between the two doses was 23 days. Patients who had previously had COVID-19 were excluded. 

Thirty patients (44.8%) were in active treatment and 37 (55.2%) were under observation or in remission.

Antibody tests were performed at the UPCM clinical laboratories using the Beckman Coulter SARTS-CoV-2 platform which detects IgG levels. 

In total, 31 patients (46%) had negative antibody results after vaccination and were considered to be vaccine non-responders. Older patients were more likely to be vaccine non-responders than younger patients. Other factors like IgG levels, number of days between vaccine doses, cancer therapy and antibody measurement did not differ between vaccine responders vs. non-responders. CLL patients were more likely to be non-responders, even when in remission. 

What does this mean for AML patients? It is still important to get the COVID-19 vaccine as there is greater than a 50% chance of it working for you (the CLL patient results increased the % of non-responders). With further study of just AML patients, it should become more clear. Asking your doctor for an antibody test to see if you have developed COVID-19 antibodies post-vaccine is a good idea. 

Until more data comes out specifically for AML patients, it is important to continue to wear masks and observe social distancing regardless of vaccination status.

 

Note: The original publication has not yet been peer-reviewed. 

 

The author Jenny Ahlstrom

about the author
Jenny Ahlstrom

Multiple myeloma patient, sister-in-law to AML patient, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by joining their disease communities and contributing their patient stories to advance a cure. Founder of the HealthTree Foundation. 

More AML News Articles

Get the latest thought leadership on AML delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.

Thanks to our HealthTree Community for AML Sponsors:

Bristol Myers Squibb
Jazz Pharmaceuticals
AbbVie
Genentech
Amgen

Follow Us

facebook instagram twitter youtube

 

Terms of Use and Privacy Policy     Newsroom     About    Donations    Find an AML Specialist     Newsletter     Learn     Connect

 

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

https://www.guidestar.org/profile/45-5354811